Adaptimmune Therapeutics plc

NasdaqGS:ADAP Lagerbericht

Marktkapitalisierung: US$162.8m

Adaptimmune Therapeutics Management

Management Kriterienprüfungen 3/4

Adaptimmune Therapeutics CEO ist Ad Rawcliffe , ernannt in Sep 2019, hat eine Amtszeit von 5.17 Jahren. Die jährliche Gesamtvergütung beträgt $2.77M , bestehend aus 23.4% Gehalt und 76.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.1% der Aktien des Unternehmens, im Wert von $169.21K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.9 Jahre bzw. 9.7 Jahre.

Wichtige Informationen

Ad Rawcliffe

Geschäftsführender

US$2.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts23.4%
Amtszeit als Geschäftsführer5.2yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements4.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder9.7yrs

Jüngste Management Updates

Recent updates

Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 03

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10
Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

Circling Back On Adaptimmune Therapeutics

Dec 15

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Sep 29

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ad Rawcliffe im Vergleich zu den Einnahmen von Adaptimmune Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$72m

Mar 31 2024n/an/a

-US$163m

Dec 31 2023US$3mUS$650k

-US$114m

Sep 30 2023n/an/a

-US$95m

Jun 30 2023n/an/a

-US$91m

Mar 31 2023n/an/a

-US$114m

Dec 31 2022US$3mUS$650k

-US$165m

Sep 30 2022n/an/a

-US$175m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$171m

Dec 31 2021US$4mUS$617k

-US$158m

Sep 30 2021n/an/a

-US$156m

Jun 30 2021n/an/a

-US$149m

Mar 31 2021n/an/a

-US$140m

Dec 31 2020US$3mUS$574k

-US$130m

Sep 30 2020n/an/a

-US$123m

Jun 30 2020n/an/a

-US$127m

Mar 31 2020n/an/a

-US$138m

Dec 31 2019US$2mUS$500k

-US$137m

Sep 30 2019n/an/a

-US$144m

Jun 30 2019n/an/a

-US$99m

Mar 31 2019n/an/a

-US$102m

Dec 31 2018US$1mUS$457k

-US$96m

Sep 30 2018n/an/a

-US$87m

Jun 30 2018n/an/a

-US$93m

Mar 31 2018n/an/a

-US$69m

Dec 31 2017US$2mUS$444k

-US$70m

Vergütung im Vergleich zum Markt: AdDie Gesamtvergütung ($USD2.77M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.46M).

Entschädigung vs. Einkommen: AdDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Ad Rawcliffe (52 yo)

5.2yrs

Amtszeit

US$2,774,041

Vergütung

Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Adrian G. Rawcliffe
CEO, Principal Accounting Officer & Director5.2yrsUS$2.77m0.10%
$ 169.2k
Helen Tayton-Martin
Co-Founder & Chief Business & Strategy Officerno dataUS$1.18m0.12%
$ 191.0k
Gavin Hilary Wood
Chief Financial Officer4.6yrsUS$1.17m0.0063%
$ 10.2k
William C. Bertrand
COO & Chief Compliance Officer7.7yrsUS$1.22m0.064%
$ 104.5k
Elliot Norry
Chief Medical Officer4.8yrsUS$1.18m0.037%
$ 60.2k
Joanna Brewer
Chief Scientific Officer2.5yrskeine Daten0.0049%
$ 7.9k
Juli Miller
VP of Corporate Affairs & Investor Relationsno datakeine Datenkeine Daten
Kerry Sharp
Senior VP & General Council9.1yrskeine Datenkeine Daten
Dana Lynch
Senior Director of Corporate Communicationsno datakeine Datenkeine Daten
John Lunger
Chief Patient Supply Officer5.3yrsUS$1.72m0.053%
$ 86.7k
Dennis Williams
Senior Vice President of Late Stage Development4.9yrskeine Datenkeine Daten
Cintia Piccina
Chief Commercial Officerless than a yearUS$2.19m0.015%
$ 24.4k

4.9yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: ADAPDas Führungsteam des Unternehmens gilt als erfahren (4.9 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Adrian G. Rawcliffe
CEO, Principal Accounting Officer & Director5.2yrsUS$2.77m0.10%
$ 169.2k
David Mott
Independent Chairman of the Board of Directors9.8yrsUS$174.83k0%
$ 0
Ali Behbahani
Independent Non-Executive Director9.8yrsUS$111.54kkeine Daten
Lawrence Alleva
Independent Non-Executive Director9.7yrsUS$128.80k0.0093%
$ 15.2k
Malcolm Brenner
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Wolf Fridman
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
John Furey
Independent Non-Executive Director6.3yrsUS$117.25k0%
$ 0
Stephan Grupp
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Michael Dustin
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Thomas Gajewski
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Andy Sewell
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Mario Sznol
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten

9.7yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ADAPDie Vorstandsmitglieder gelten als erfahren (9.7 Jahre durchschnittliche Amtszeit).